Tirzepatide represents the next generation of incretin therapy with potentially even greater efficacy, and retatrutide may push the boundaries further still
Even with excellent clinical trial safety data, individual responses may vary
The estimated mean change in body weight at week 68 was 20.4% with CagriSema versus 3.0% with placebo (a difference of about 17 percentage points), and more CagriSema participants reached weight-loss thresholds of 5%, 20%, 25%, and 30% than placebo
The injections are relatively painless, with most patients experiencing only a slight pinch at the injection site
For most healthy adults without a documented B12 deficiency, there is usually no medical benefit to receiving routine B12 injections , and they are unlikely to boost energy in the absence of deficiency
Unlike complete growth hormone, it doesnt raise IGF-1 levels or impact blood sugar control